Why the study?
Practical evidence-based recommendations for diagnosis and treatment of acute and chronic heart failure were updated in the 2016 ESC Guidelines to address advances since 2012.
Provides a comprehensive Czech summary of the 2016 ESC Heart Failure Guidelines, introducing the new HFmrEF class and therapies like sacubitril/valsartan.
Standardizes HF care with HFmrEF category and sacubitril/valsartan; extends 2012 ESC guidelines via updated evidence synthesis.
republika b III.interní klinika, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha, Česká republika c I. interní kardioangiologická klinika, Lékařská fakulta Masarykovy univerzity a Fakultní nemocnice u sv.Anny v Brně, Brno, Česká republika ČESKÁ KARDIOLOGICKÁ SPOLEČNOST THE CZECH SOCIETY OF CARDIOLOGY Autoři původního dokumentu ESC v plném znění [1,2]: Piotr Ponikowski a Adriaan A. Voors jménem autorů pracovní skupiny European Society of Cardiology (ESC) Task Force for the diagnosis and treatment of acute and chronic heart failure
No takes yet. Share an insight, caveat, or question.
Špinar et al. (2016) conducted a review in Acute and chronic heart failure. Guideline-directed medical and device therapy was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: